Innovent Biologics receives US FDA clearance to initiate phase 1 clinical trial of novel oral GLP-1R agonist, IBI3032: San Francisco Wednesday, August 6, 2025, 14:00 Hrs [IST] Inn ...

We sat down with Lauretta Katsriku, global category leader, Collagen, at Rousselot, to discuss the company’s Nextida GC and its health benefits. We also discuss improving food system sustainability, ...

Novo Nordisk A/S’s sales showed the weakest growth in four years as the Danish drugmaker loses ground to Eli Lilly & Co. in ...

Fitness influencer Ilene, at 66, is inspiring women over 50 to get in shape the healthy way. In a post on Instagram, she ...

Linda Yaccarino’s experience will be instrumental in developing innovative programs focusing on the future of peptide ...

Jefferies has upgraded its rating to 'hold' from 'underperform' and hiked the target price to Rs 1,950 from Rs 1,350.

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Linda Yaccarino, the former X CEO who left the social media company in the wake of yet another Elon Musk controversy, has ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...